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A B S T R A C T
We demonstrate the evolution of the clinical presentation and outcomes for patients with clinically localized prostate
cancer (PC) treated with radical retropubic prostatectomy (RRP) at our department, emphasizing epidemiologic signifi-
cance of changes during the 10-year period. We assessed the annual trends for changes in patients age, preoperative pros-
tate specific antigen (PSA), preoperative versus postoperative stages and Gleason grades, organ confined status and sur-
gical margin status. A total of 488 RRPs were performed from January 1996 to December 2005 with the annual fre-
quency increased from 8 to 129 (1512.5%). Mean patient age increased from 61.5 to 66.12 years in 2005, with the percent-
age of men aged more than 70 years increased from 12.5 to 26.5%, respectively. The detection of PC based solely on patho-
logical PSA levels (as indication for prostate biopsy) rose impressively from 25.5 to 70% and the rates of postoperative or-
gan-confined disease also increased significantly from 25 to 74.7%. Mean preoperative PSA decreased from 16.7 to 9.89
ng/mL. On the contrary, there was an increase in percentage of patients with preoperative PSA values ranging from 4 to
10 ng/mL (from 20 to 65.4%). Positive surgical margin rate decreased from 49.4 to 25% and percent of patients receiving
neoadjuvant therapy decreased from 78.5 to 5.4%. Proportion of patients who were undergraded decreased from 75.1 to
31.7%. The rates of understaging have remained relatively stable over the years. During the study period, PC was in-
creasingly detected by prostate biopsy on the basis of a pathological PSA level only and shifted significantly to more or-
gan-confined stages with more favourable outcomes for pathological variables due to a more accurate assessment of clin-
ical stage prior to surgery, reduced use of neoadjuvant therapy and improved surgical technique. Our data also argue
strongly that routine PSA testing should be expanded and not restricted.
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Introduction
The incidence of prostate cancer (PC) has increased
worldwide during the past fifteen years1,2. This trend
may be a result of the widespread application of prostate
specific antigen (PSA) testing and increased life expec-
tancy2. It is the most common non-skin cancer in men in
the United States, and is second only to lung cancer as a
cause of cancer deaths in men3. In Croatia, it is the sec-
ond most common cancer in men (second only to lung
cancer)4,5. Prior to the widespread use of PSA testing in
asymptomatic men, PC was detected mainly via digital
rectal exam (DRE), increased prostatic phosphatase lev-
els and after transurethral resection; and only 25% of
newly diagnosed PCs were clinically organ-confined after
surgery6,7. Since the advent of PSA testing in Western
countries, the percentage of newly diagnosed organ-con-
fined and locally advanced disease has increased to up-
wards of 80%3. With no PSA screening programme, such
a dramatic change has not been reported in Croatia, but
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there has been a significant increase in the annual detec-
tion rate since the introduction of PSA testing in early
90s. The operative management of localised PC has un-
dergone important changes in the past decade, with ma-
jor improvements in surgical technique, a greater em-
phasis on structured preoperative staging and asses-
sment of quality of life. Radical retropubic prostatectomy
(RRP) and recently, laparoscopic radical prostatectomy,
has become the preferred treatment for selected patients
with early stage PC and today, it remains the gold stan-
dard for treatment of localised PCs with favourable prog-
noses (i.e., tumor stage T1a-T2, PSA<10 ng/mL, and bi-
opsy Gleason score<7)8,9. The 10-year cancer-specific
survival rate of RRP was recently reported to be 90%10.
The treatment is highly effective; therefore, patients
usually enjoy long-term survival, indicating that the
treatment should guarantee a high quality of life. With
an increasing chance of finding early stage PC, the proce-
dure has also gained popularity among Croatian urolo-
gists in several hospitals over the last decade.
Purpose of this epidemiologic report is to evaluate our
experience in RRP. We retrospectively evaluated the pre-
operative and postoperative data of patients who under-
went RRP for localized PC in our institution. Changes
and advances in patient selection criteria over time and
clinical outcome data are evaluated and discussed em-
phasizing annual changes over ten year period.
Material and Methods
We retrospectively analyzed preoperative clinical data
and outcomes of 488 consecutive patients treated with
RRP for clinically localized PC at our institution (De-
partment of Urology »Sestre milosrdnice« University
hospital, Zagreb, Croatia) between January 1996 and De-
cember 2005.
A computerized database was created and data ab-
stracted directly from the records; the information ab-
stracted and entered included the date of surgery, the age
of the patient, the medical history regarding use of
neoadjuvant therapy (antiandrogens for 3 months prior
to RRP), preoperative serum PSA level, clinical stage
(DRE status), prostate biopsy Gleason grade and number
of biopsy cores sampled, the final pathological stage and
grade and surgical margin status. The last PSA value
and DRE status obtained prior to prostate biopsies was
used in the analysis. Patients underwent a bilateral stag-
ing pelvic lymphadenectomy with or without frozen sec-
tion, followed by a RRP under general anaesthesia. The
RRP was carried out using the similar technique as origi-
nally described by Walsh, with small modifications, de-
pending on the surgeon11. All procedures were performed
by urologists at our department with different surgical
skills and experience. The frozen section analysis after
pelvic lymphadenectomy was carried out only in patients
with higher risk for extraprostatic extension of the dis-
ease (PSA>20 ng/mL, and biopsy Gleason score>7). The
RRP specimens, including prostate, seminal vesicles, and
bilateral pelvic lymph nodes, were examined microscopi-
cally after routine preparation. All specimens were sco-
red according to the Gleason grading system12. Micro-
scopic extension of malignant cells to the inked surface of
the resected specimen was interpreted as a positive sur-
gical margin. The patients were staged according to the
2002 TNM staging criteria13.
Preoperative and postoperative clinical and patholog-
ical data were analyzed and compared for annual chan-
ges over the observation period. Descriptive statistics
and time-flow charts were used to analyze trends over
time (calendar year).
Results
A total of 488 men underwent RRP for localized PC at
our department between January 1996 and December
2005, with the annual frequency of surgical interven-
tions increased markedly, from 8 to 129 (1512.5%) during
the observation period. In 24 cases with gross lymph
node metastasis at frozen section, only bilateral lymph
node dissection was done and the proportion decreased
rapidly over the study period due to more accurate preop-
erative staging and more rigorous selection of patients
suitable for surgery (lower PSA levels, lower biopsy Glea-
son grades). Overall, there was no early peri-operative
mortality. Figure 1 demonstrates an increase in RRP
rate, especially in last two years with more than two hun-
dred operations performed.
The distribution of preoperative (clinical) tumour sta-
ge with time is illustrated in Figure 2. It shows the dra-
matic stage migration occurring in the PSA era. The con-
tribution of preoperative cT1c disease, based solely on
pathological PSA levels as indication for prostate biopsy
(DRE negative), rose significantly, from 25.5% in 1996 to
75% in 2005.
Mean age of patients at diagnosis was 61.5 years in
1996. It is gradually increasing yearly and in 2005 it was
66.12 years (overall range 44 to 75 years) (Figure 3). The
annual rates of those aged greater than 70 years old were
12.5%, 7.7%, 16%, 20.4%, 19.4%, 22.6%, 25.8%, 25.6%,
24.7% and 26.1%, respectively.
G. [timac et al.: Ten Year Experience in Radical Prostatectomy, Coll. Antropol. 31 (2007) 4: 1055–1060
1056




















Fig. 1. The number of patients undergoing RRP in 1 year inter-
vals, RRP – radical retropubic prostatectomy, LDN – lymphade-
nectomy only due to ex- tempore positive lymph nodes.
Mean preoperative PSA value has gradually decrea-
sed from 17.7 ng/mL in 1996 to 9.89 ng/mL in 2005 (over-
all range 0.4 to 51 ng/mL) (Figure 4). On the contrary,
distribution of preoperative PSA values over time dem-
onstrates increase in percentage of patients with preop-
erative PSA values ranging from 4.0 to 10.0 ng/mL (from
20% in 1996 to 65.4% in 2005) (Figure 5).
Traditionally, for patients with abnormal PSA values
and/or abnormal DRE findings, six core transrectal ul-
trasound (TRUS) guided prostate biopsies were perfor-
med (from 1994 to 1997). The rates of patients with eight
and more cores per biopsy taken increased markedly and
were 0%, 0%, 10%, 23%, 28%, 27%, 31%, 40%, 49% and
80% in the observation period indicating a tendency for
more accurate sampling of the prostate tissue and more
accurate preoperative staging of prostate cancer.
Of 488 patients, 150 (30.7%) received neoadjuvant
therapy for more than 3 months prior to RRP. The an-
nual rates of patients receiving neoadjuvant therapy
markedly decreased and were 78.5%, 75.2%, 44.3%, 46%,
34.9%, 36.1%, 33.1%, 23%, 15.3% and 5.4% the observa-
tion period, respectively (Figure 6).
The distribution of postoperative tumour stages with
time is shown in Figure 7. Annual distributions of post-
operative pT2 and pT3 stages demonstrate migration to-
ward localized disease. Annual rates of postoperative
pT2 (organ confined disease) stages were 25 %, 37.5%,
44.4%, 46.3%, 72.7%, 76.2%, 62.7%, 71.4%, 73% and
74.7%, from 1996 to 2005 (Figure 7).
The proportion of patients with margin positivity de-
creased steadily during the observation period, from
49.4% in 1996 to 25% in 2005, which also reflects ad-
vancements in surgical skill and more rigorous patient
selection criteria over the observation period (Figure 8).
Diagram showing changes in distribution of preopera-
tive Gleason grades indicates tendency of the pathologist
to assign a higher Gleason grade in prostate biopsy speci-
mens (Figure 9), so there is significant decline in under-
grading over the years (from 75.1% in 1997 to 31.7% in
2005) (Figure 10).
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Fig. 2. Preoperative stage migration: the contribution of nonpal-
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Fig. 6. The annual rates of patients receiving neoadjuvant ther-
apy prior to RRP.
The rates of patients who were understaged were
60.0%, 50.0%, 66.7%, 76.9%, 64.0%, 51.2%, 72.2%, 64.3%,
67.3% and 77%, over the years (Figure 11).
Discussion
Serum PSA testing is now a commonly used method
for detecting organ-confined PC amenable to RRP as a
method of local, and potentially curative, therapy. Fur-
thermore, prostate cancers are being detected earlier,
before becoming clinically palpable on digital rectal ex-
amination, because of PSA testing. This allows for ear-
lier diagnosis, more therapeutic options, and better pa-
tient selection for surgical therapy. In Croatia, PSA
testing was introduced in early 90s and the use of RRP
systematically begun at our department in the middle
1990s, before most urological centres. From 1994 to 1996
only few RRPs were performed, and before that all pa-
tients with localized disease were treated with hormonal
therapy, surgical castration or watchful waiting (careful
observation with intention to treat). At our centre there
was a dramatic increase in the number of procedures,
from 1996 to 2000, followed by a more stabilising trend
in 2003, 2004 and 2005. Today, the annual RRP rate is
over 150. The dramatic increase in the number of proce-
dures over the study period was caused mainly by an in-
troduction and popularisation of serum PSA testing to
the community and primary health care providers. The
reason for the relative stabilisation in RRP rate in the
past few years is less certain than the dramatic increase,
but it may reflect the decreasing incidence of prostate
cancer that has been attributed to the depletion of the
prevalent pool of undiagnosed cancers14,15.
In contrast to the findings of Stamey et al and Moul et
al, our results showed an annual trend of increasing age
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Fig. 7. Postoperative stage migration: the contribution of organ
confined disease (pT2).
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Fig. 9. Changes in distribution of preoperative (biopsy) Gleason
grades.
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Fig. 11. The annual trends in proportion of patients who were
»understaged«.
at surgery16,17 Furthermore, the percentage of men aged
more than or equal to 70 years old increased from 12.5%
in 1996 to 26.5% by 2005. Similar trend was observed in
other studies18–20. It is mainly because our patient selec-
tion criteria extended over the age 70 years due to more
recently increased life expectancy of men in Croatia.
PSA is the most important preoperative selection and
staging tool followed by biopsy Gleason grade and clinical
stage. Studies from leading institutions with a large
number of RRPs recommend reduction of preoperative
PSA levels. The PSA level at the time of diagnosis is a
general surrogate for tumor volume or burden, and Fig-
ure 4 documents the marked shift to lower PSA values
over time in our institution. Mean preoperative PSA
value has gradually decreased in the study period, but
there was an increase in percentage of patients with pre-
treatment PSA values ranging from 4.0 to 10.0 ng/mL
(Figure 5) which reflects an advancement in patient
selection criteria for RRP over the years. Similarly, men
with a PSA value >20 ng/mL are at high risk of surgi-
cally incurable disease, and this group declined from
30.1% in 1995 to 4.2% by 2005.
As to the selection of patients by clinical staging, the
absolute contributions of cT1c disease (detected by an
elevated PSA level only and prostate biopsy afterwards)
have steadily increased and accounted for 70% of all
cases in 2005. By the same token, the proportion of
patients with palpable disease (T2) declined from 74.5%
in 1995 to only 30% by 2005. The dramatic increase in
PSA-detected, nonpalpable, or clinical T1c disease has
been documented in other series. Most notably, Arai et al.
documented that T1c disease increased from 13.9% to
37.9% between 1991 and 1998 in a combined series of 7
centres in Japan including 638 patients21. Similarly, Sta-
mey et al. found that cT1c disease went from 10% of
cases in 1988 to 73% by 199616. The increased use of PSA
testing is probably the main contributing factor to the
increase in detection rate and proportion of clinical T1c
disease16,22,23. Repeated TRUS biopsy, better and gentler
tissue sampling with eight or more cores per biopsy
taken in patients with an initially negative sextant bi-
opsy is an equally important contributing factor. Tradi-
tionally, six core TRUS guided biopsies were performed
at our department (from 1994 to 1997). The contribution
of laterally directed TRUS biopsies with eight and more
cores per patient at our institution increased markedly
up to 80% in 2005. A less significant factor might be that
fewer patients undergo transurethral resection of the
prostate. Overall, there is a significant decrease in inci-
dental carcinomas in higher stages.
With the advent of PSA testing many countries have
seen a significant clinical and pathological stage migra-
tion toward organ-confined disease, such is in our ca-
se18–25. On final pathological staging, the proportion of
patients with pathologically organ confined disease in-
creased remarkably during study period from 25% in
1996 to 74.7% in 2005. Similarly, our colleagues from
Graz in Austria reported the rates of postoperative or-
gan-confined disease increasing from 47% in 1993 to 79%
in 200426. In their centre, the annual frequency of RRPs
increased from 43 in 1994 to 160 in 2004, which is com-
parable to our results26.
Radical prostatectomy is a demanding urological op-
eration. A key indicator of the quality of a surgical resec-
tion is the incidence of positive surgical margins in pa-
tients with organ-confined cancer. The surgical tech-
nique must be the most precise and rigorous possible be-
cause positive surgical margins expose the patient to a
risk of disease recurrence directly related to the surgical
procedure. The margin positivity in our study decreased
from 49.4 % in 1996 to 25% in 2005. This is somewhat
higher than in other RRP series, although evaluation of
the CaPSURE data base with patients recruited from 29
mainly community and some academic urology practice
sites reveals a positive surgical margin rate of 34% with
6% of pathological reports indeterminate18,19,27.
There were also significant annual changes in the
proportion of percent preoperative Gleason grade 5, 7
and 8 cancer, with proportion of Gleason grades 7 and 8
increasing and proportion of Gleason grades 4 and 5 de-
creasing over a 10-year period which indicates tendency
of the pathologist to assign a higher primary Gleason
grade in prostate biopsy specimens, so there is signifi-
cant decline in undergrading over the study period. More
accurate grading can be also explained by a decreasing
percentage of patients who have received neoadjuvant
therapy prior to surgery (from 78.5% in 1996 to 5.4% in
2005). The rates of patients who were understaged have
remained relatively stable over the years as seen on Fig-
ure 11.
During the observation period, there is a marked an-
nual increase in RRP rate with an increasing contribu-
tion of nonpalpable cancers, diagnosed solely on patho-
logical PSA levels (as indication for prostate biopsy). The
increase in the number of RRPs during the past decade
might be a result of the improved detection rate rather
than a real increase in incidence among Croatian men.
An increase in the rate of surgical interventions is also a
result of continuing education of urologists, exchange of
ideas, published technical improvements in the surgical
procedure, and other factors, ultimately benefiting the
patient by improving outcomes28. Also, an increase in or-
gan-confined disease in patients undergoing RRP might
be biased by better and more rigorous patient selection.
Specifically, a greater proportion of low-risk patients may
be selected for RRP. On the other hand, higher risk pa-
tients may ultimately choose external beam radiotherapy
over RRP. Overall, there was a trend toward more favour-
able outcomes for pathological variables (an increased
percentage of organ confined disease, decreased margin
positivity, decreased understaging and a decreased inci-
dence of positive lymph node metastasis on frozen sec-
tion analysis). These data are the result of careful patient
selection for surgery, progressive refinement of operative
technique and improvements in perioperative manage-
ment at our department.
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Conclusions
The RRP remains the procedure of choice for the cure
of localized PC in patients with long life expectancy and
good overall status. As seen from our data during the
10-year period, PC was increasingly detected on the basis
of a pathological PSA level only and shifted significantly
to more organ-confined stages due to a more accurate as-
sessment of clinical stage prior to surgery, reduced pa-
tient morbidity, reduced use of neoadjuvant therapy and
improved surgical technique. With a time delay, these
findings are consistent with trends observed at several
well-known academic institutions in the region and in
the USA26,29–31. Our data also argue strongly that current
PSA testing has resulted in the detection of clinically
more organ confined cancers, and that PSA testing and
routine DRE should be expanded and not restricted.
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POBOLJA[ANJE KLINI^KE SLIKE I ISHODA NAKON RADIKALNE PROSTATEKTOMIJE
U BOLESNIKA S LOKALIZIRANIM KARCINOMOM PROSTATE – PROMJENE U
DESETOGODI[NJEM RAZDOBLJU
S A @ E T A K
U radu prikazujemo promjene klini~ke slike i ishoda nakon radikalne retropubi~ne prostatektomije (RRP) u bolesnika
s lokaliziranim karcinomom prostate tretiranih na na{em odjelu, nagla{avaju}i epidemiolo{ki zna~aj kretanja u razdoblju
od deset godina. Analizirali smo godi{nje promjene dobi bolesnika, preoperativnih vrijednosti prostata specifi~nog anti-
gena (PSA), preoperativnih i postoperativnih stadija i gradusa tumora, statusa lokaliziranosti tumora i statusa kirur{kih
rubova. Od sije~nja 1996 do studenog 2005 u~injeno je 488 zahvata, s godi{nim porastom od 8 do 129 (1512,5%). Prosje~na
dob bolesnika porasla je od 61,5 u 1996 do 66,12 godina u 2005, uz istovremeni porast udjela bolesnika starijih od 70
godina od 12,5 do 26,5 % u istom razdoblju. Udio bolesnika u kojih je detektiran karcinom prostate samo na osnovi pato-
lo{kih vijednosti PSA (kao indikacije za biopsiju prostate) porastao je impresivno od 25,5 do 70 % u 2005, uz istovremeni
porast udjela postoperativno lokalizirane bolesti od 25 do 74%. Prosje~na godi{nja vrijednost preoperativnog PSA smanji-
la se sa 16,7 na 8,9 ng/mL. S druge strane bilje`imo porast udjela bolesnika s rasponom preoperativnih vrijednosti PSA
izme|u 4 i 10 ng/mL (od 20 u 1996 do 65,4% u 2005). Stope pozitivnih kirur{kih rubova smanjile su se od 49,4 do 25% u
ispitivanom razdoblju. Udio bolesnika koji su primali neoadjuvantnu terapiju smanio se sa 78,5 na 5,4%. Udio bolesnika u
kojih je bio podcijenjen gradus tumora smanjio se sa 75,1 na 31,7%. Stope podcjene stadija ostale su relativno stabilne
tijekom godina. U ispitivanom razdoblju sve vi{e je karcinoma detektirano biopsijom prostate samo na osnovi povi{enih
vrijednosti PSA, te postoji zna~ajna migracija stadija ka lokaliziranoj bolesti. Ovo je rezultat {ire primjene PSA, to~nije
procjene preoperativnog stadija, poo{travanja kriterija pri selekciji pacijenata pogodnih za operativni zahvat, te pobolj-
{anja kirur{ke tehnike. Na{i rezultati sugeriraju da bi rutinsko PSA testiranje trebalo biti stimulirano, a ne ograni~avano.
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